secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001104659-22-037086
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals' Corporate Controller resigns; CEO appointed as interim principal financial officer
--------------------------------------------------------------------------------

- Michael Meluzio resigned as Corporate Controller and interim principal financial/accounting officer on March 18, 2022.
- Brian M. Strem, Ph.D., President and CEO, appointed as principal financial and accounting officer effective March 18, 2022.
- Company engaged Danforth Advisors, LLC for interim finance and accounting services until a permanent replacement is found.
- Resignation not due to any disagreement with company's operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922037086/0001104659-22-037086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922037086/tm2210197d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-037086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer